Clinical Results and Pharmacokinetics of Sorafenib in Chronic Hemodialysis Patients with Metastatic Renal Cell Carcinoma in a Single Center

Abstract

Treatment with sorafenib of patients with metastatic renal cell carcinoma undergoing hemodialysis appears to be feasible, but we express some concern about the higher incidence of serious adverse events even with the reduced dose. However, clinical efficacy was not compromised.